﻿<?xml version="1.0" encoding="utf-8"?><!--RSS Genrated: Thu, 30 Apr 2026 20:07:37 GMT--><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:ev="http://purl.org/rss/1.0/modules/event/"><channel><title>American Pharmacists Association</title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/June-2025/rss/3704</link><atom:link href="http://www.pharmacist.com/Publications/Pharmacy-Today/June-2025/rss/3704" rel="self" type="application/rss+xml" /><description>RSS document</description><item><dc:creator><![CDATA[Roger Selvage]]></dc:creator><title><![CDATA[Recognizing benzodiazepine-induced neurological dysfunction]]></title><link>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/recognizing-benzodiazepine-induced-neurological-dysfunction</link><description><![CDATA[  Thao Anh Mai, PharmD; Kami Johnston, PharmD; Jeffrey D. Gold, PharmD, BCPP  

   

 An estimated 30.6 million adults in the United States will use benzodiazepines within the past year. ...]]></description><pubDate>Wed, 07 May 2025 16:00:00 GMT</pubDate><guid>http://www.pharmacist.com/Publications/Pharmacy-Today/Article/recognizing-benzodiazepine-induced-neurological-dysfunction</guid><dc:identifier><![CDATA[3fea3d08-a011-4455-a0c4-c8d47a98398c-3422]]></dc:identifier></item></channel></rss>